secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001628280-23-022276
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Therapeutics shareholders approve doubling authorized shares, stock plan amendment; director resigns
--------------------------------------------------------------------------------

- Jeffrey Berkowitz resigned from Board effective June 15, 2023; no disagreement with company.
- Shareholders approved charter amendment to increase authorized common shares from 240M to 480M.
- Shareholders approved amendment to 2022 Stock Plan to add 6,250,000 shares to authorized issuance pool.
- Four Class I directors elected: J. Martin Carroll, Sheldon L. Koenig, Stephen Rocamboli, Tracy M. Woody.
- Tracy Woody appointed Chairperson of Compliance Committee, replacing Berkowitz.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023022276/0001628280-23-022276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828023022276/espr-20230615.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-022276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer